Meeting
2021 ASCO Annual Meeting
Update on safety and efficacy of a phase 1/2 of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN).
Authors
Alain Patrick Algazi
Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA
Alain Patrick Algazi , Dhaval Shah , William Smith , Timothy J. Panella , Dong Moon Shin , Justine Yang Bruce , Ramzi Melhem , Jean S. Campbell , Lauren Abell , Marie-Louise Fjaellskog , John K. Celebi , Robert Hamilton Pierce , Ann Wild Gramza
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04034225
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6029)
DOI
10.1200/JCO.2021.39.15_suppl.6029
Abstract #
6029
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Efficacy of PD-1 inhibitors in the treatment of advanced gastrointestinal tumors and the effect on T-lymphocyte subsets and IL-6 levels in patients.
First Author: XinCheng He
Poster
2019 ASCO Annual Meeting
A multicenter, phase II study of soluble LAG-3 (Eftilagimod Alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC).
First Author: Julio Antonio Peguero
Poster
2016 ASCO Annual Meeting
Phase 2 study of the safety and efficacy of pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for advanced melanoma (KEYNOTE-022).
First Author: Georgina V. Long
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang